CNTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Connect Biopharma Holdings Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.90−0.01 (-0.72%)
Close on Oct 19, 2026
- Market cap
- $56.58M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Connect Biopharma's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
2 buys · 0 sales
Net bought $4.37M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Wubin Pan | 6,026,813 | 9.60% | 13G (passive) | Apr 14, 2026 |
| Zheng Wei | 5,015,960 | 9.00% | 13G (passive) amendment | Dec 31, 2025 |
| Neil Shahrestani | 4,338,534 | 6.90% | 13G (passive) amendment | Jun 30, 2026 |
| Braden M Leonard | 4,264,400 | 6.77% | 13G (passive) | Sep 30, 2026 |
| James Huang | 13,160,000 | 21.20% | 13D (active) amendment | Mar 31, 2026 |
| Panacea Innovation Limited | 12,000,000 | 21.50% | 13D (active) amendment | Nov 24, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Barry D. Quart | Chief Executive Officer, Director | 224,034 | 0.36% | Mar 16, 2026 |
| Lisa Peraza | Senior Vice President, Finance | 45,189 | 0.07% | Mar 16, 2026 |
| David Leslie Szekeres | President | 215,739 | 0.34% | Mar 16, 2026 |
| Jean I. Liu | Director | 11,779 | 0.02% | Jul 1, 2026 |
| Kleanthis Gabriel Xanthopoulos | Director | 86,554 | 0.14% | Jul 1, 2026 |
| James Huang | Director | 13,310,000 | 21.14% | Jun 2, 2026 |
| James A. Schoeneck | Director | – | – | Mar 16, 2026 |
| Karen J. Wilson | Director | 10,000 | 0.02% | Mar 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kleanthis Gabriel Xanthopoulos Director | Jun 30, 2026 | Award | +3,738 | – | – | 86,554 |
| Jean I. Liu Director | Jun 30, 2026 | Award | +6,718 | – | – | 11,779 |
| James Huang Director | May 29, 2026 | Buy | +150,000 | $2.48 | $372.00K | 13,310,000 |
| Kleanthis Gabriel Xanthopoulos Director | Mar 31, 2026 | Award | +2,816 | – | – | 82,816 |
| Jean I. Liu Director | Mar 31, 2026 | Award | +5,061 | – | – | 5,061 |
| James Huang Director | Mar 31, 2026 | Buy | +1,160,000 | $3.45 | $4.00M | 13,160,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Innovation Limited Panacea 10% Owner | Nov 24, 2025 | 2,000,000 | $6.00M | Nov 24, 2025 | The Ordinary Shares were purchased in multiple open market transactions from 2022 through September 2025. |
| Zheng Wei 10% Stockholder | Nov 21, 2025 | 650,000 | $2.07M | Nov 21, 2025 | Compensation- Stock Award |
| Inc BioFortune 10% Stockholder | Nov 18, 2025 | 500,000 | $1.25M | Nov 18, 2025 | Acquired under Employee Incentive Plan as employee of the Securities Issuer |
| Zheng Wei 10% Stockholder | Oct 1, 2025 | 200,000 | $305.94K | Oct 1, 2025 | Compensation- Stock Award |
| Zheng Wei 10% Stockholder | Jun 11, 2025 | 39,775 | $32.22K | Jun 11, 2025 | Compensation-Stock Award |
| Capital Healthcare Fund LP RA 10% Stockholder | Dec 18, 2023 | 1,765,788 | $1.67M | Dec 18, 2023 | IPO Investment |
| RA Capital Nexus Fund, L.P. 10% Stockholder | Dec 18, 2023 | 295,650 | $279.03K | Dec 18, 2023 | Open Market Purchase |
| RA Capital Nexus Fund, L.P. 10% Stockholder | Dec 12, 2023 | 36,959 | $33.26K | Dec 12, 2023 | Open Market Purchase |
| Capital Healthcare Fund LP RA 10% Stockholder | Dec 12, 2023 | 220,738 | $198.66K | Dec 12, 2023 | Open Market Purchase |
| RA Capital Nexus Fund, L.P. 10% Stockholder | Nov 27, 2023 | 151,778 | $195.79K | Nov 27, 2023 | IPO Investment |
| Capital Healthcare Fund LP RA 10% Stockholder | Nov 27, 2023 | 906,504 | $1.17M | Nov 27, 2023 | Open market purchase |
| Capital Healthcare Fund LP RA 10% Stockholder | Nov 21, 2023 | 471,732 | $971.77K | Nov 21, 2023 | IPO Investment |
| RA Capital Nexus Fund, L.P. 10% Stockholder | Nov 21, 2023 | 78,983 | $162.70K | Nov 21, 2023 | IPO Purchase |